Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

Science reported that the National Institutes of Health (NIH) director, Jay Bhattacharya, dismissed all members of the agency’s top external advisory body, the Advisory Committee to the Director (ACD) ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

In just 3 years, the Influenza Vaccines Research and Development (R&D) Roadmap Initiative has demonstrated important ...

Moderna's Spikevax vaccine is the first to receive full approval for use in children aged 6 months to 11 years with a high-risk health issue.

The Atal Incubation Centre (AIC) at CSIR-Centre for Cellular and Molecular Biology (CCMB) is progressing with larger-scale ...

CSIR-Centre for Cellular and Molecular Biology (CCMB) Atal Incubation Centre (AIC) is planning to go ahead with the next stage larger-scale trials of the indigenously developed mRNA vaccine technology ...

Warming trends across North America have helped establish West Nile virus (WNV) as an endemic disease in New York state, and ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.